• Rezolute’s first-quarter FY27 net loss widened year over year to $18.49 million.
• Cash, cash equivalents and investments in marketable securities fell 17% from June 30 to $90 million at September 30, 2026.
• Enrollment in the Phase 3 upLIFT tumor HI study is complete, with topline results expected by mid-December 2026.
• A BLA submission for ersodetug in one or potentially both indications is planned for 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051605PRIMZONEFULLFEED9871384) on November 05, 2026, and is solely responsible for the information contained therein.